125354-16-7

Basic information

• Product Name: Docetaxel
• Synonyms: 10-Acetyldocetaxel;10-Acetyltaxotere;Docetaxal;PNU 101383;ACETYLDOCETAXEL, 10-(P);Docetaxel N-Debenzoyl-N-(tert-butoxycarbonyl)taxol;DOCETAXOL;Docetaxel
• CAS NO: 125354-16-7
• Molecular Formula: C₄₅H₅₅NO₁₅
• Molecular Weight: 849.922
• EINECS: 1533716-785-6
• Mol File: 125354-16-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 201-203 °C(Solv: methanol (67-56-1))
• Boiling Point: 901.4 °C at 760 mmHg
• Flash Point: 499 °C
• Appearance: /
• Density: 1.36 g/cm³
• Vapor Pressure: 5.54E-35mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 11.20±0.46(Predicted)
• CAS DataBase Reference: Docetaxel(CAS DataBase Reference)
• NIST Chemistry Reference: Docetaxel(125354-16-7)
• EPA Substance Registry System: Docetaxel(125354-16-7)

Safety Data

• Hazardous Substances Data: 125354-16-7(Hazardous Substances Data)

Usage

Description

Docetaxel is a semisynthetic derivative of Paclitaxel, an antimitotic agent that promotes the assembly of micro-tubules and inhibits their de-polymerization to free tubulin. It is available in single-dose vials for intravenous administration and is widely distributed with the highest concentration in the hepatobiliary system. Docetaxel is highly plasma protein bound and primarily eliminated in the feces with a terminal half-life of 11 hours.

Uses

Used in Anticancer Applications:
Docetaxel is used as an anticancer agent for the treatment of breast, non-small cell lung cancer (NSCLC), and prostate cancers. It has also been utilized in non-FDA-approved treatment of head, neck, gastric, bladder, and refractory ovarian cancers.
Used in Pharmaceutical Industry:
Docetaxel is used as an active pharmaceutical ingredient in the formulation of cancer treatment drugs. It is administered intravenously and has a similar adverse effects profile to paclitaxel but also includes reversible fluid retention, which can be minimized with sodium restriction and pretreatment with corticosteroids. Peripheral neuropathy, fatigue, muscle pain, and fever are common side effects associated with docetaxel treatment.

InChI:InChI=1/C45H55NO15/c1-23-28(58-39(53)33(50)32(26-16-12-10-13-17-26)46-40(54)61-41(4,5)6)21-45(55)37(59-38(52)27-18-14-11-15-19-27)35-43(9,29(49)20-30-44(35,22-56-30)60-25(3)48)36(51)34(57-24(2)47)31(23)42(45,7)8/h10-19,28-30,32-35,37,49-50,55H,20-22H2,1-9H3,(H,46,54)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

Upstream product

• 220985-01-3 2'-O-tert-butyldimethylsilyl-7-O-triethylsilyldocetaxel 
• 115437-21-3 7-(triethylsilyl)baccatin III 
• 1144034-14-9 10-acetyl-2'-TBDMS-docetaxel 
• 27548-93-2 baccatin III 
• 114915-13-8 C₄₈H₅₆Cl₃NO₁₇ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 133524-70-6 13-(O-2R-hydroxy-3S-amine-phenylpropionyl)-baccatin III 
• 1246748-59-3 C₆₆H₇₃NO₁₆Si 
• 1246748-58-2 C₆₆H₇₅NO₁₆Si 
• 670254-71-4 (2*,4S,5R)-methyl N-tert-butoxycarbonyl-2-(4'-methoxy)phenyl-4-phenyl-1,3-oxazolidine-5-methionate 
• 124605-42-1 methyl (2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionate 
• 114915-24-1 7(2,2,2-trichloroethyloxycarbonyl)-13-cinnamoyl baccatin III_. 
• 103150-33-0 7-(2,2,2-trichloroethyloxycarbonyl)baccatin III 
• 140-10-3 (E)-3-phenylacrylic acid 

Downstream Products

• 114915-20-7 Docetaxel 
• 133524-70-6 13-(O-2R-hydroxy-3S-amine-phenylpropionyl)-baccatin III 
• 173101-56-9 C₄₈H₅₃NO₁₄ 

Relevant articles and documents

Synthesis of docetaxel and butitaxel analogues through kinetic resolution of racemic β-lactams with 7-O-triethylsilylbaccatin III

(Chemical Equation Presented) The kinetic resolution of racemic cis-4-phenyl- and cis-4-tert-butyl-3-hydroxy-β-lactam derivatives with 7-O-triethylsilylbaccatin III yielded paclitaxel and butitaxel analogues with high diastereoselectivity. The results demonstrated that the tert-butyldimethylsilyl protecting group at the C3-hydroxy group of the β-lactams provided optimum kinetic resolution in comparison with the sterically less demanding triethylsilyl group and the larger triisopropylsilyl group. In addition, it was found that the C4 β-lactam substituents also influenced diastereoselectivity. The C4 tert-butyl-β-lactams provided better diastereoselectivity than the corresponding C4 phenyl β-lactams.

Novel crystalline forms of anticancer compound CX1409 and preparation method and application of novel crystalline forms of anticancer compound CX1409

The invention relates to the field of compounds, in particular to two novel crystalline forms of an anticancer compound CX1409. A crystalline form A of the anticancer compound CX1409 is determined byusing a powder X-ray diffraction method, wherein characteristic diffraction peaks are shown at 4.3 degree, 8.7 degree, 11.0 degree, 12.5 degree, 13.0 degree, 14.1 degree, 15.4 degree, 17.4 degree, 18.4 degree, 19.6 degree, 20.1 degree, 20.8 degree, 21.7 degree, 27.0 degree, 29.0 degree, 30.6 degree and 31.4 degree in an X-ray powder diffraction spectrum expressed by a diffraction angle of 2 theta+/-0.3 degree; a crystalline form B of the anticancer compound CX1409 is determined by using the powder X-ray diffraction method, wherein characteristic diffraction peaks are shown at 4.9 degree, 5.4degree, 5.8 degree, 6.4 degree, 8.0 degree, 9.4 degree and 12.9 degree in an X-ray powder diffraction spectrum expressed by a diffraction angle of 2 theta +/-0.3 degree. The above two crystalline forms are not reported, outlines of the two crystalline forms are clear, and the two crystalline forms can be perfectly reproduced; besides, the two crystalline forms have the advantages of being good instability of preparation and high in yield and purity, can be applied to anti-tumor drugs, and have wide application prospects.

NOVEL AMINO ACID MOLECULE AND USES THEREOF

There is provided novel amino acid molecules and processes for their preparation. There is also provided novel amino acid molecules and their use in processes for preparing the compounds that are useful for the synthesis of paclitaxel, and docetaxel, the anticancer drug.